This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Therapeutic proteins and antibodies are one of the most important and rapidly growing segments of the pharmaceutical
industry. By 2016, yearly spending on brand biologics will reach $60 billion. But affordability of these life saving drugs is
a challenge specifically in the developing world. There is a pragmatic solution on the horizon for safe, affordable, biosimilar
versions of these critical therapies. Biosimilars have been proved safe and effective in Europe for last seven years but in USA the
guidelines from US FDA to develop biosimilars is still awaited.
As we know the genesis of biosimilars is providing cheap, affordable drugs for the masses, specifically in emerging markets
where affordability of critical drugs is a major concern. This presentation will focus on how to design the development in a
cost effective way keeping a close watch on Critical Quality Attributes (CQAs) of the drug. What and how much is required to
establish the biosimilarity of the drug is more important.
There is at least a 100 fold improvement in assays available during the development of innovator molecules and assays
available now. It is now possible to accurately quantitate the chemical status of each residue in a protein molecule and measure
minute structural variance using various orthogonal approaches.
In addition, the relevance and extent of clinic trails for innovators and for biosimilars will be discussed too.
Harish Shandilya is heading Biocharacterization of therapeutic proteins at INTAS Biopharmaceuticals Ltd. Ahmedabad, India. He is working with
INTAS for last 6 years now. Prior to this assignment he has developed clones for many biotherapeutic proteins. He is a molecular biologist by
training and has worked at various prestigious institutions in India and abroad. He did his post doctoral work at Vanderbilt University Medical
Center, Nashville, USA. Before joining Intas, he was associated with University of Pittsburgh, USA. He has done his Ph.D. degree (1999) from M.D.
University, Rohtak, India in collaboration with ICMR, India. He has published more than 20 research papers in reputed journals. He has experience
of coordinating multiple biosimilar product development programs for domestic and regulated market projects.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals